3SBio Revenue and Competitors
Estimated Revenue & Valuation
- 3SBio's estimated annual revenue is currently $71.6M per year.
- 3SBio's estimated revenue per employee is $155,000
Employee Data
- 3SBio has 462 Employees.
- 3SBio grew their employee count by -8% last year.
3SBio's People
Name | Title | Email/Phone |
---|
3SBio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is 3SBio?
关于三生制è¯é›†å›¢ 三生制è¯é›†å›¢æ˜¯ä¸€å®¶é›†ç ”å‘ã€ç”Ÿäº§å’Œé”€å”®ä¸ºä¸€ä½“的生物制è¯é¢†å†›ä¼ä¸šï¼Œè‡´åŠ›äºŽä»¥é«˜å“质的è¯å“æ高患者生å˜è´¨é‡ï¼Œä¸ºäººç±»å¥åº·é€ ç¦ã€‚ç›®å‰ï¼Œé›†å›¢æ‹¥æœ‰80余项国家å‘明专利授æƒï¼Œ30ä½™ç§ä¸Šå¸‚产å“,覆盖肿瘤ã€è‡ªèº«å…ç–«ã€è‚¾ç—…ã€ä»£è°¢åŠçš®è‚¤ç§‘ç‰æ²»ç–—领域。集团拥有抗体è¯ç‰©å›½å®¶å·¥ç¨‹ç ”究ä¸å¿ƒä»¥åŠç”Ÿç‰©è¯å’ŒåŒ–è¯åŒå¹³å°çš„4å¤§ç ”å‘ä¸å¿ƒï¼Œå…±æœ‰25ç§åœ¨ç ”产å“,其ä¸16ç§ä½œä¸ºå›½å®¶ä¸€ç±»æ–°è¯æ£åœ¨ç ”å‘,并拥有符åˆGMPæ ‡å‡†çš„6大生产基地。未æ¥ï¼Œä¸‰ç”Ÿåˆ¶è¯é›†å›¢å°†ç»§ç»ç§‰æŒâ€œç爱生命ã€å…³æ³¨ç”Ÿå˜ã€åˆ›é€ 生活â€çš„ç†å¿µï¼Œå…¨åŠ›æ‰“é€ å…¨çƒé¢†å…ˆçš„ä¸å›½ç”Ÿç‰©åˆ¶è¯ä¼ä¸šã€‚ About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of “Care for Life, Cherish Life, Create Life†to create a world's leading bio-pharmaceutical company in China.
keywords:N/AN/A
Total Funding
462
Number of Employees
$71.6M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
3SBio News
rhEPO Market Overview, High Growth Opportunities, Segmentation, Trends By 2022-2028 | 3SBio, Biosidus, NCPC Genetech, Shanghai Chemo, Ahua...
3sbio; Shanghai Chemo; Chengdu Diao; Ncpc Genetech; Kyowa Hakko Kirin; Shandong Kexing; Ahua Pharmaceutical; Biosidus; Dragon Pharma.
3SBio continued to be rated A in MSCI ESG Ratings in 2021, surpassing 78% of the world's biotech companies. The Company has been named in the...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $117.8M | 469 | N/A | N/A |
#2 | $79.4M | 512 | -2% | N/A |
#3 | $131.5M | 513 | 1% | N/A |
#4 | $183.6M | 534 | 0% | N/A |
#5 | $9570M | 699 | 5% | N/A |